










Impact of COVID-19 on drugs in development

In May 2020, we conducted a syndicated study to assess the impact of COVID-19 on biopharmaceutical market access with payers and advisors in the US, Europe, Brazil, and China. Our questions covered vaccines and therapies, both COVID-19 specific and others


Sample									Total
Payers / advisors	35	6	6	6	6	6	6	6	77

Here is a snapshot of the expected impact of COVID-19 on payers' budget allocation and willingness to pay for other drugs in development

Both US and EU payers expect neutral to negative impact on budget allocation for Cell and Gene Therapies and Orphan drugs, but EU payers more inclined to anticipate positive impact on generics & biosimilars




Cell and gene therapies / orphan drugs



"Alternative reimbursement models are going to have to be discussed, particularly around gene therapy and orphan drugs because of the cost and budgetary impact. Formularies and employers are going to increase their restrictions on traditional therapies because of the increased cost and the rise of unemployment."

PBM, US

Generics & biosimilars



"Access will be faster and budget will be higher for generics and biosimilars because they are cost-saving. But slower for the others."

Payer, UK

"For all products there will be higher cost pressure in terms of price negotiation for new drugs; there is no willingness to pay more for generics if they're produced in Europe."

Payer, Germany

Data based on interim sample of n=60



If this study is potentially of interest to your company and you would like to receive a more detailed overview of the results, including individual insights by market, please contact us:

info@researchpartnership.com | researchpartnership.com